Stopping cotrimoxazole prophylaxis increases the risk of serious bacterial infections and malaria, even at high CD4 cell counts, in people taking antiretroviral therapy in Uganda, results of a randomised trial show.
The results were presented on Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, by Professor Jonathan Levin of the UK’s Medical Research Council.
Read more:
If you enjoyed this article and would like to build a career in global health, we offer a range of MSc programmes covering health and data, infectious and tropical diseases, population health, and public health and policy.
Available on campus or online, including flexible study that works around your work and home life, be part of a global community at the UK's no.1 public health university.